Reducing the incidence of infection after caesarean section: implications of prophylaxis with antibiotics for hospital resources.
OBJECTIVE
To estimate the cost effectiveness of giving prophylactic antibiotics routinely to reduce the incidence of wound infection after caesarean section.


METHODS
Estimation of cost effectiveness was based, firstly, on a retrospective overview of 58 controlled trials and, secondly, on evidence about costs derived from data and observations of practice.


METHODS
Trials included in the overview were from obstetric units in several different countries, including the United Kingdom. The costing study was based on data referring to the John Radcliffe Maternity Hospital, Oxford.


METHODS
A total of 7777 women were included in the 58 controlled trials comparing the effects of giving routine prophylactic antibiotics at caesarean section with either treatment with a placebo or no treatment. Cost estimates were based on data on 486 women who had caesarean sections between January and September 1987.


METHODS
Cost effectiveness of prophylaxis with antibiotics.


RESULTS
The odds of wound infection are likely to be reduced by between about 50 and 70% by giving antibiotics routinely at caesarean section. Forty one (8.4%) women who had caesarean section were coded by the Oxford obstetric data system as having developed wound infection. The additional average cost of hospital postnatal care for women with wound infection (compared with women who had had caesarean section and no wound infection) was estimated to be 716 pounds; introducing routine prophylaxis with antibiotics would reduce average costs of postnatal care by between 1300 pounds and 3900/100 pounds caesarean sections (at 1988 prices), depending on the cost of the antibiotic used and its effectiveness.


CONCLUSIONS
The results suggest that giving antibiotics routinely at caesarean section will not only reduce rates of infection after caesarean section but also reduce costs.
Mugford
M
M
National Perinatal Epidemiology Unit, Radcliffe Infirmary, Oxford.
Kingston
J
J
Chalmers
I
I
D000667:Ampicillin / Q000627:therapeutic use*; D002440:Cefoxitin / Q000627:therapeutic use*; D002585:Cesarean Section / Q000009:adverse effects / Q000191:economics; D003362:Cost-Benefit Analysis; D004739:England; D005260:Female; D006748:Hospital Departments / Q000191:economics*; D006801:Humans; D009775:Obstetrics and Gynecology Department, Hospital / Q000191:economics*; D011181:Postnatal Care / Q000191:economics; D011247:Pregnancy; D011292:Premedication / Q000191:economics; D012189:Retrospective Studies; D012307:Risk Factors; D013223:Statistics as Topic; D013530:Surgical Wound Infection / Q000191:economics / Q000517:prevention & control*
D002440:Cefoxitin; D000667:Ampicillin